Ravandi, Farhad <br/><br/>
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).  [electronic resource] 

 -  Leukemia research  09 2016 
 - 92-100 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2016.07.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Cytarabine--adverse effects<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Enzyme Inhibitors--pharmacology<br/>Female<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Proto-Oncogene Proteins c-mdm2--antagonists & inhibitors<br/>Salvage Therapy<br/>Survival Analysis<br/>Treatment Outcome